Chronic illness drug developer Sigilon Therapeutics has filed to go public after raising almost $200m from investors including Eli Lilly.
Sigilon Therapeutics, a US-based chronic illness therapy developer backed by pharmaceutical firm Eli Lilly, has filed for a $100m initial public offering on the Nasdaq Global Market. Founded in 2015, Sigilon has built a drug development platform dubbed Shielded Living Therapeutics which it is using to create therapeutic molecules that can make up for proteins, antibodies…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.